|Mr. Jon P. Stonehouse||CEO, President & Executive Director||1.15M||5.33M||1961|
|Mr. Anthony J. Doyle||Senior VP & CFO||726.42k||N/A||1980|
|Ms. Alane P. Barnes||Senior VP, Chief Legal Officer & Corporate Secretary||655.33k||N/A||1966|
|Dr. William P. Sheridan MBBS||Chief Development Officer||784.09k||4.4M||1955|
|Dr. Yarlagadda S. Babu||Chief Discovery Officer||691.45k||1.25M||1953|
|Dr. Helen M. Thackray FAAP, M.D.||Chief Research & Development Officer||844k||N/A||1968|
|Mr. Charles K. Gayer||Senior VP & Chief Commercial Officer||643.43k||N/A||1971|
|Mr. Michael L. Jones||Executive Director of Finance & Principal Accounting Officer||N/A||N/A||1970|
|Mr. John D. Bluth||Chief Communications Officer||N/A||N/A||1973|
|Ms. Stephanie Angelini||Chief People Officer||N/A||N/A||N/A|
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor for complement-mediated diseases; and Galidesivir, to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
BioCryst Pharmaceuticals, Inc.’s ISS governance QualityScore as of 28 November 2023 is 5. The pillar scores are Audit: 8; Board: 2; Shareholder rights: 8; Compensation: 5.